Company intelligence / Profile preview

Global Apheresis

San Francisco, California, USAglobalapheresis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Global Apheresis is pioneering the use of Therapeutic Plasma Exchange (TPE) as both a treatment and prophylactic intervention for chronic inflammation, age-related diseases, neurodegenerative disorders, and over 80 autoimmune conditions. Their recent study with the Buck Institute demonstrated measurable reversal of biological aging in adults over 50 using TPE, supported by multiomics analysis and epigenetic age tracking[1][8]. TPE is also positioned as an adjunct or alternative to pharmacologic therapies for certain indications.

Therapeutic areas: OtherImmunologyNeurology
Modalities: DeviceNon-pharmacological therapy (Therapeutic Plasma Exchange)
Industry: Therapeutic Medical Devices

Partnerships

Buck Institute for Research on Aging[1]

Beyond the preview

Go deeper on Global Apheresis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global Apheresis.